Caveolin-3 TLR4在老年心力衰竭并发心律失常患者血清中的表达及预后价值

doi:10.3969/j.issn.1006-6233.2025.04.014

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1355 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨小窝蛋白-3(Caveolin-3)、Toll样受体4(TLR4)在老年心力衰竭(HF)并发心律失常患者血清中的表达及预后评估价值。方法: 选取于2022年6月至2023年6月在本院进行治疗的老年心力衰竭并发心律失常患者96例为研究组,同期心力衰竭未并发心律失常患者98例为对照组。记录患者随访12个月内发生的不良心血管事件,根据结果将患者分为预后不良组(n=33),预后良好组(n=63)。采用酶联免疫吸附法检测血清中Caveolin-3、TLR4的表达水平;多因素Logistic回归模型分析心力衰竭并发心律失常患者预后不良的影响因素;受试者工作特征(ROC)曲线分析血清Caveolin-3、TLR4对心力衰竭并发心律失常患者预后不良的预测价值。结果: 与对照组相比,研究组患者血清中TLR4水平升高,Caveolin-3水平降低,差异有统计学意义(t=8.393、10.228,均P<0.05);预后不良组与预后良好组患者心功能分级经比较,差异具有统计学意义差异(χ²=35.024,P<0.05);预后不良组患者血清TLR4水平均高于预后良好组,Caveolin-3、LVEF水平均低于预后良好组(t=6.510、7.280、3.816,均P<0.05);多因素Logistic回归分析,心功能分级及TLR4水平为发生预后不良的危险因素,LVEF、Caveolin-3水平为发生预后不良的保护因素(P<0.05);ROC曲线结果显示,血清Caveolin-3、TLR4水平预测心力衰竭并发心律失常患者预后不良的AUC别为0.775、0.854,二者联合预测的AUC为0.898,高于单一指标检测(Z=2.964,P=0.003,Z=2.111,P=0.035)。结论: 在心力衰竭并发心律失常患者血清中Caveolin-3水平降低,TLR4水平升高,联合检测二者可作为评估心力衰竭并发心律失常患者预后不良的血清标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	柯春凤
	曹溢
	唐燕
	周嫱

关键词 ：心力衰竭, 心律失常, 小窝蛋白-3, Toll样受体4, 预后

Abstract：Objective: To investigate the expression and prognostic value of caveolin-3 and Toll-like receptor 4 (TLR4) in the serum of elderly patients with heart failure (HF) complicated by arrhythmia. Methods: A total of 96 patients with heart failure complicated by arrhythmia admitted to our hospital from June 2022 to June 2023 were included as the study group, and 98 patients without heart failure complicated by arrhythmia were included as the control group. Adverse cardiovascular events that occurred during the 12-month follow-up period were recorded, and the patients were assigned to a poor prognosis group (n=33) and a good prognosis group (n=63) based on the results. Enzyme linked immunosorbent assay was applied to detect the expression levels of Caveolin-3 and TLR4 in serum. Multivariate logistic regression was applied to analyze the factors affecting the prognosis of patients with heart failure complicated by arrhythmia. The receiver operating characteristic (ROC) curve was plotted to analyze the predictive value of Caveolin-3 and TLR4 levels for poor prognosis in patients with heart failure complicated by arrhythmia. Results: Compared with the control group, the serum TLR4 level was higher and Caveolin-3 level was lower in the study group (t=8.393, 10.228, all P<0.05). The difference in cardiac function grading between the poor prognosis group and the good prognosis group was statistically obvious (χ²=35.024, P<0.05). The serum TLR4 level in the poor prognosis group was higher than that in the good prognosis group, while the Caveolin-3 and LVEF levels were lower than those in the good prognosis group (t=6.510, 7.280, 3.816, all P<0.05). Multivariate logistic regression analysis showed that cardiac function grading and TLR4 level were risk factors for poor prognosis, while LVEF and Caveolin-3 levels were protective factors for poor prognosis (P<0.05). ROC curve showed that the AUC of predicting poor prognosis in patients with heart failure complicated by arrhythmia by serum Caveolin-3 and TLR4 levels was 0.775 and 0.854, respectively. The AUC predicted by the combination of the two was 0.898, higher than that of single indicator detection (Z=2.964, P=0.003, Z=2.111, P=0.035). Conclusion: The serum level of Caveolin-3 is decreased and TLR4 is increased in patients with heart failure complicated by arrhythmia. The combined detection of the two can be used as serum markers to evaluate the poor prognosis of patients with heart failure complicated by arrhythmia.

Key words： Heart failure Arrhythmia Caveolin-3 Toll-like receptor 4 Prognosis

基金资助:四川省卫生健康委员会科研课题,(编号:19PJ010)

引用本文:

柯春凤, 曹溢, 唐燕, 周嫱. Caveolin-3 TLR4在老年心力衰竭并发心律失常患者血清中的表达及预后价值[J]. 河北医学, 2025, 31(4): 614-619.
KE Chunfeng, CAO Yi, TANG Yan, et al. Expression and Prognostic Value of Caveolin-3 and TLR4 in Serum of Elderly Patients with Heart Failure Complicated by Arrhythmia. HeBei Med, 2025, 31(4): 614-619.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2025.04.014 或 http://www.hbyxzzs.cn/CN/Y2025/V31/I4/614

[1] Zheng YY,Wu TT,Hou XG,et al.Serum a-1 antitrypsin as a novel biomarker in chronic heart failure[J].ESC Heart Fail,2023,10(5):2865-2874.
[2] Radhoe SP,Brugts JJ.CardioMEMS^TM:a tool for remote hemodynamic monitoring of chronic heart failure patients[J].Future Cardiol,2022,18(3):173-183.
[3] Zhang Y,Xiong X,Wang J,et al.Prognostic value of serum IGF-1,Gal-3,and PTX-3 levels in elderly patients with chronic heart failure[J].Am Transl Res,2024,16(4):1393-1400.
[4] Zhang Z,Fang Q,Du T,et al.Cardiac-specific Caveolin-3 overexpression prevents post-myocardial infarction ventricular arrhythmias by inhibiting ryanodine receptor-2 hyperphosphorylation[J].Cardiology,2020,145(3):136-147.
[5] Vaez H,Soraya H,Garjani A,et al.Toll-like receptor 4 (TLR4) and AMPK relevance in cardiovascular disease[J].Adv Pharm Bull,2023,13(1):36-47.
[6] 葛均波,徐永健,王辰.内科学[M].第9版.北京:人民卫生出版社,2018.124-138.
[7] Bredy C,Ministeri M,Kempny A,et al.New York Heart association(NYHA)classification in adults with congenital heart disease:relation to objective measures of exercise and outcome[J].Eur Heart Qual Care Clin Outcomes,2018,4(1):51-58.
[8] Amaechi UM,Aiwuyo HO,Ewelukwa C,et al.Assessing iron status in chronic heart failure patients by using serum ferritin and transferrin saturation levels:a cross-sectional descriptive study[J].Cureus,2023,15(5):e39425.
[9] 杨静静.慢性心力衰竭患者血清NT-proBNP、Hcy水平变化及其对心律失常的预测价值[J].黑龙江医药科学,2024,47(1):168-170.
[10] Frantz S,Hundertmark MJ,Schulz-Menger J,et al.Left ventricular remodelling post-myocardial infarction:pathophysiology,imaging,and novel therapies[J].Eur Heart,2022,43(27):2549-2561.
[11] Youssef ME,Abdelrazek HM,Moustafa YM,et al.Inhibition of Toll-like Receptor-4 expression for amelioration of myocardial injury in diabetes:A meta-analysis[J].Clinics (Sao Paulo),2022,77(1):100137-100145.
[12] Yuan J,Yin X,Jiang H.Inhibition of toll-like receptor-4 expression for amelioration of myocardial injury in diabetes:a meta-analysis[J].Clinics (Sao Paulo),2022,77(1):100137-100145.
[13] 曾润生,梁玉鹃,蔡承哲,等.外周血TLR4、CysC联合检测对冠心病患者PCI术后1年内ISR发生的预测价值[J].吉林医学,2023,44(11):3063-3067.
[14] He M,Qiu J,Wang Y,et al.Caveolin-3 and Arrhythmias:Insights into the Molecular Mechanisms[J].J Clin Med,2022,11(6):1595-1608.
[15] Benzoni P,Gazzerro E,Fiorillo C,et al.Caveolin-3 and caveolin-1 interaction decreases channel dysfunction due to caveolin-3 mutations[J].Int Mol Sci,2024,25(2):980-998.
[16] Guo P,Hu S,Liu X,et al.Caveolin-3alleviates diabetic cardiomyopathy via inhibiting NDUFA10-mediated mitochondrial dysfunction[J].Transl Med,2024,22(1):390-409.
[17] 刘宇彤,郭俊凡,张岳甫,等.睡眠剥夺对缺血再灌注后心肌Caveolin-3表达与细胞凋亡的影响[J].武汉大学学报(医学版),2024,45(1):14-18.